This site is intended for healthcare professionals residing in Canada.

Visit Pfizer AcademySearch

Menu

Close

Sign InLog Out
  • EN
ProductsTherapy AreasExplore ContentExplore
ContentGo to Explore ContentEventsMaterialsVideosPatient SupportContact
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Français

Menu

Close

About Prevnar 13About Prevnar 13Mechanism of ActionSerotype coverageIncidence of IPD and Colonization dataExperienceImmunogenicityDosingDosingDosingEfficacy and Safety ProfileEfficacy and Safety ProfileEfficacy profileSafety profileGuidelinesGuidelinesGuidelinesResourcesResourcesMaterialsVideos
Product MonographImportant Safety Information 
ImmunogenicityAntibody concentrationsPercentage of Subjects with Pneumococcal Anti-capsular Polysaccharide IgG Antibody Concentrations ≥0.35 μg/mL for the 7 Common Serotypes (1 month after the 3-dose primary infant series at 2, 4, and 6 months of age)Adapted from the Prevnar 13 Product Monograph.

The non-inferiority criterion was met when compared to the lowest response of the 7 common serotypes in Prevnar (7-valent) recipients. For serotype 3, the percentage of subjects, who received Prevnar 13 and reached the threshold, was 63.5% and 73.3% in the USA studies and the non-inferiority criterion was not met when compared to Prevnar (7-valent) response against serotype 6B (92.8%, study 6096A1-004) or serotype 23F (95.2%, study 6096A1-3005), respectively.1

Antibody responses to booster doses following 2-dose or 3-dose infant primary series in different studies were comparable for all 13 vaccine serotypes.1 IgG: immunoglobulin G.Reference:Prevnar® 13 Product Monograph. Pfizer Canada ULC. 2022. 
NEXT

Dosing

 Visit page Loading
EXPLORE MORE

Guidelines

 Visit page Loading
PP-PRV-CAN-0016-EN

To report an adverse event, please call 1-866-723-7111

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out

© Pfizer Canada ULC 2024. All rights reserved. The information is intended only for healthcare professionals resident in Canada. ®Pfizer Inc., used under license.

PP-UNP-CAN-0145-EN
You are now leaving Pfizerpro.ca website
Links to other sites are provided as a convenience to the viewer, and should not be taken as an endorsement of the sites or an association with their owners. Pfizer Canada accepts no responsibility for the content of linked sites.
You are now leaving the PfizerPro Portal.
You are about to view resources made available by Pfizer Academy. 
These resources include learning programs and upcoming events. By selecting Go to link below, you acknowledge and certify that you are a Canadian Healthcare Professional.
PP-UNP-CAN-0013 EN